Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
No holdings reported for quarter Q4 2018 |
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
MICROSOFT CORP | 15 | Q2 2024 | 5.8% |
APPLE INC | 15 | Q2 2024 | 4.7% |
NVIDIA CORPORATION | 15 | Q2 2024 | 7.8% |
ALPHABET INC | 15 | Q2 2024 | 3.3% |
META PLATFORMS INC | 15 | Q2 2024 | 4.0% |
ALPHABET INC | 15 | Q2 2024 | 3.0% |
ADVANCED MICRO DEVICES INC | 15 | Q2 2024 | 3.0% |
ARCH CAP GROUP LTD | 15 | Q2 2024 | 2.5% |
AMAZON COM INC | 15 | Q2 2024 | 2.3% |
CHUBB LIMITED | 15 | Q2 2024 | 1.9% |
View Polar Capital Holdings Plc's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
Arcutis Biotherapeutics, Inc. | February 13, 2024 | 6,297,688 | 6.7% |
AVADEL PHARMACEUTICALS PLC | February 13, 2024 | 6,751,782 | 7.5% |
Celldex Therapeutics, Inc. | February 13, 2024 | 3,135,871 | 5.7% |
NanoString Technologies Inc | February 13, 2024 | 3,975,000 | 8.3% |
Revance Therapeutics, Inc. | February 13, 2024 | 3,169,239 | 3.6% |
Spyre Therapeutics, Inc. | February 13, 2024 | 500,000 | 1.0% |
Aeglea BioTherapeutics, Inc. | July 28, 2023 | 3,936,198 | 5.0% |
INFINITY PHARMACEUTICALS, INC. | February 14, 2023 | 2,071,242 | 2.3% |
Quotient LtdSold out | February 14, 2023 | 0 | 0.0% |
Summit Therapeutics Inc.Sold out | February 14, 2023 | 0 | 0.0% |
View Polar Capital Holdings Plc's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
N-PX | 2024-08-30 |
13F-HR | 2024-08-14 |
13F-HR | 2024-05-15 |
13F-HR | 2024-02-14 |
SC 13G/A | 2024-02-13 |
SC 13G/A | 2024-02-13 |
SC 13G/A | 2024-02-13 |
SC 13G/A | 2024-02-13 |
SC 13G | 2024-02-13 |
SC 13G | 2024-02-13 |
View Polar Capital Holdings Plc's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.